Publications by authors named "M Nijkeuter"
Background: Pulmonary embolism is an important cause of preventable mortality. Treatment strategies depend on risk stratification. High-risk patients, and some intermediate-high-risk patients, require urgent reperfusion therapy.
View Article and Find Full Text PDFArticle Synopsis
- After 3 months of anticoagulation treatment for venous thromboembolism (VTE), clinicians must decide on continuing or stopping the treatment, ideally guided by the VTE-PREDICT calculator that estimates risks of recurrence and bleeding.
- A study involved clinicians evaluating fictional VTE cases; some made duration proposals without calculator input (Group A), while others used the calculator to inform their decisions (Group B).
- Results showed no overall difference in proposed durations between the two groups, yet many in Group A adjusted their recommendations after seeing the calculator risks, noting its usefulness, particularly for patients at high bleeding risk.
Article Synopsis
- The POCHET biobank aims to investigate bleeding complications during catheter directed thrombolysis (CDT) for acute limb ischemia (ALI) and to identify potential new biomarkers for predicting these complications, as current reliance on fibrinogen lacks strong evidence.
- This multicenter prospective project includes patients undergoing CDT, collecting blood samples before and during treatment while assessing bleeding outcomes through a defined protocol.
- By combining patient data and blood samples, the biobank seeks to advance research on bleeding risks associated with CDT and evaluate various biomarkers, contributing to improved patient care and safety.
Introduction: Cancer-related pulmonary embolism (PE) is associated with poor prognosis. Some decision rules identifying patients eligible for home treatment categorize cancer patients at high risk of complications, precluding home treatment. We sought to assess the effectiveness and the safety of outpatient management of patients with low-risk cancer-associated PE.
View Article and Find Full Text PDFBackground: A decision to stop or continue anticoagulation after 3 months of anticoagulation for venous thromboembolism (VTE) should be made by weighing individual risks of recurrence and bleeding.
Objectives: To determine the optimal ratio of recurrence risk reduction to increase the risk of bleeding in terms of maximizing quality-adjusted life years (QALYs) gained.
Methods: Using a microsimulation model, outcomes within 5 years were simulated after assigning extended treatment if absolute recurrence risk reduction outweighed absolute increase in clinically relevant bleeding risk (International Society on Thrombosis and Haemostasis definition), weighted by a certain ratio.